New treatment options for pediatric convulsive status epilepticus after failure of first-line benzodiazepines
There are limited options as second line treatment in convulsive status epilepticus (CSE), both in underage and adult populations with sufficient level of scientific evidence to be approved by regulatory institutions (Shorvon and Trinka, 2018).
Phenytoin is the current standard of care for second-line treatment of paediatric CSE after failure of first-line benzodiazepines, but is only effective in 60% of cases and is associated with considerable adverse effects. A newer anticonvulsant, levetiracetam, has some favorable characteristics with potentially better tolerability and efficacy.
Please continue here.
